Survival Analysis for Patients with ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401

Lessons Learned Alectinib confers a pronounced survival benefit in patients with ALK rearrangement‐positive non‐small cell lung cancer and a poor performance status. Survival benefit of alectinib for patients with a poor performance status was consistent regardless of the presence of central nervous...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2020-04, Vol.25 (4), p.306-e618
Hauptverfasser:	Iwama, Eiji, Goto, Yasushi, Murakami, Haruyasu, Tsumura, Shinsuke, Sakashita, Hiroyuki, Mori, Yoshiaki, Nakagaki, Noriaki, Fujita, Yuka, Seike, Masahiro, Bessho, Akihiro, Ono, Manabu, Nishitsuji, Masaru, Akamatsu, Hiroaki, Morinaga, Ryotaro, Akagi, Takanori, Shimose, Takayuki, Tokunaga, Shoji, Yamamoto, Nobuyuki, Nakanishi, Yoichi, Sugio, Kenji, Okamoto, Isamu
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!